Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | PLAU | P00749 | 3/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371415 | 0.90 | ELANE (0.53) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6375106 | 0.87 | L3MBTL1 (0.52) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6370749 | 0.85 | L3MBTL1 (0.39) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6370191 | 0.85 | PTGS2 (0.40) | ELANEF2PLAUCTRB1MAP2K4 | |
| SCHEMBL22801748 | 0.84 | MAP2K4 (0.52) | MAP2K4ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL22801648 | 0.84 | MAP2K4 (0.52) | MEN1KMT2AMAP2K4ALDH1A1HPGD | |
| SCHEMBL6370637 | 0.82 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6369581 | 0.81 | ELANE (0.39) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6369994 | 0.80 | F12 (0.42) | ELANEF2PLAUCTRB1MEN1 | |
| SCHEMBL1709876 | 0.79 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | ELANE 4606/4885F2 3965/4885PLAU 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.